Phase III Clinical Trials Show Ruboxistaurin Reduce Rates of Vision Loss Caused by Diabetic Retinopathy
"These data are exciting because they show that ruboxistaurin has the potential to be the first oral therapy to specifically reduce the risk of vision loss caused by diabetic retinopathy," said Lloyd Paul Aiello, MD, PhD, lead investigator of the study, director, Beetham Eye Institute & Section on Eye Research, Joslin Diabetes Center, and associate professor of ophthalmology, Harvard Medical School in Boston, MA. "This could be an important clinical development for the millions of people around the world who are at risk for vision loss caused by this serious disease."
Diabetic retinopathy is a common complication in diabetic patients, affecting an estimated 4.1 million adults in the US, and thus regarded as the leading cause of blindness in the working aged population (age 40 and above). In February this year, Eli Lilly has submitted a New Drug Application to the FDA, which granted ruboxistaurin a priority review.
More details from Eli Lilly's press release.
.jpg)
Comment Preview